-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|April 1, 2024

Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

The panel discusses remaining gaps in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment and shares perspectives on optimal practices and care settings for managing this disease.


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.